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INTRODUCTION
Allergy to hymenoptera venom is a potentially life-threaten-
ing disease, but long-term control is possible through venom 
immunotherapy (VIT). Its efficacy is high, protecting around 
95% of patients allergic to Vespidae and 75%-85% of those aller-
gic to honey bees.1,2 Sometimes, it is necessary to increase the 
conventional dose to achieve protection.3
Unfortunately, routine diagnostic tests, skin tests, and specific 
IgE are not feasible for evaluating the clinical protection of pa-
tients following VIT.4-8 Five years after immunotherapy, more 
than 50% of patients have detectable specific IgE and no signifi-
cant changes in cutaneous tests sensitivity.9 Although revealing 
studies about genetics and other biomarkers are ongoing,10-12 
currently the in vivo test that provides more information about 
individual clinical protection achieved by a particular treat-
ment is the sting challenge test. Nevertheless, it has several 
drawbacks, such as risk of anaphylaxis, difficulty in obtaining 
some species of hymenoptera, and the fact that it requires a fair 
amount of time, as well as human and material resources. In-
deed, the main inconvenience of this test is that it does not offer 
a 100% negative predictive value when only one sting is tolerat-
ed, due to the influence of the quality of the venom and several 
individual biological factors associated with clinical reactivi-
ty.9,13,14 Repeated stings, however, increase the complexity and 
cost of patient follow-up, and are not recommended due to the 
elevated risk of adverse reactions.
Undoubtedly, a non-invasive test would be optimal to detect 
unprotected patients. The basophil activation test (BAT) has 
been used for the diagnosis of hypersensitivity to inhalants, la 
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tex, food, and drugs.15-17 It is a very sensitive and specific meth-
od to diagnose venom allergy.18-22 Its high specificity is due to 
the fact that it studies cellular response following antigen stim-
ulation in real time. This makes it possible to monitor VIT by 
using serial BAT determinations, at both short-and the long 
term follow-up and in cross-sectional approaches.16,23-29 In a 
long-term study on induction of tolerance after a complete pe-
riod of at least 4.5 years of VIT monitored by using BAT,28 22 of 
the 23 patients treated tolerated sting challenge after finishing 
VIT. The clinical tolerance was correlated with an approximate-
ly 4-fold decrease in basophil responsiveness, and this drop 
was sustained 3 to 6 months after the sting. In contrast, in a sin-
gle patient who had a positive challenge the basophil response 
did not change during VIT. This significant change in basophil 
reactivity was also assessed in other studies that compared 17 
bee or wasp allergic patients who tolerated field sting after fin-
ishing VIT with 14 other reactive patients whose basophil acti-
vation did not change after completion of VIT.26 In another 
study, a group of 27 patients treated with bee venom IT for al-
most 5 years tolerated sting challenge, and BAT achieved a neg-
ative predictive value of 100%.29 In children, the decrease in ba-
sophil reactivity 4 years after VIT has been assessed in 85% of a 
series of 31 patients, and approximately a half of them reported 
tolerance to field sting.30
The following prospective study examined changes in baso-
phil reactivity over a complete VIT period of 5 years. A cross-
sectional study was also performed in 2 other groups of pa-
tients, one comprising patients treated for almost 3 years, and 





The subjects of the study were 10 patients allergic to hyme-
noptera venom presenting systemic reactions, 8 men and 2 
women, between the ages of 14 and 76 years. Two of them were 
allergic to Apis mellifera, 3 to Vespula germanica, and 5 to 
Polistes dominulus (Table 1). 
The diagnosis was established using serum specific IgE mea-
surements (ImmunoCap, Thermo Fisher Scientific, Waltham, 
MA, USA) and skin prick and intradermal tests (Venom Pharm-
algen, ALK-Abello, Madrid, Spain). Endpoint titration was used 
for intradermal tests (10-5 to 10-1 µg/mL), according to the 
guidelines.31
VIT was prescribed for all of them (Pharmalgen, ALK-Abello, 
Madrid, Spain). A 6-week build-up schedule was followed up 
to a maintenance dose of 100 mcg, administered monthly. 
Serial BAT was performed before beginning VIT and over the 
following period of 4.5-5 years. Baseline BAT determination 
was made at the time of diagnosis (0m, basal); the next analysis 
was performed 1 month after finishing the VIT build-up phase 
(1m), immediately before receiving the first monthly mainte-
nance dose, and subsequent measurements were taken after 3, 
6, 12, 18, 24, and 60 months of treatment, named as 3m, 6m, 
12m, 18m, 24m, and 60m, respectively. The samples were taken 
1 month after starting the maintenance dose —which is on 
study— was administered. The analyses that could not per-
formed or were not valuable at the mentioned times due to in-
tercurrent medical processes or non-attendance of patients, 
were considered lost, to avoid a hypothetical bias caused by its 
performance 1 or more months later; as all the results corre-
sponding to each time were analyzed in block.
Ten healthy controls without detectable venom-specific IgE or 
clinical histories of hymenoptera sting adverse reactions were 
studied.
Cross-sectional series
A cross-sectional study was also performed to examine baso-
phil activation in a group of patients who were in treatment for 
more than 3 years (n=6), and in another group of patients who 
Table 1. A series of patients followed up prospectively
Patient Age Gender Venom Clinical picture sIgE (kU/l) Prick test ID test Time of field sting
  1 77 M Apis Anaphlylaxis 14.4 Negative Positive (0.01 mcg/mL)
  2 38 F Vespula Anaphlylaxis 0.41 Negative Positive (0.01 mcg/mL)
  3 31 M Polistes Anaphlylaxis 0.98 Negative Positive (1 mcg/mL)
  4 42 M Vespula Urticaria 18.8 Negative Positive (0.1 mcg/mL) 2 m    
  5 51 F Vespula Anaphlylaxis 0.46 Negative Positive (0.1 mcg/mL) 2 m and 12 m
  6 22 M Polistes Anaphlylaxis 2.29 Negative Positive (0.1 mcg/mL)
  7 14 M Apis Anaphlylaxis 4.5 Negative Positive (0.01 mcg/mL) 12 m
  8 15 M Polistes Anaphlylaxis 3.3 Negative Positive (0.1 mcg/mL)
  9 52 M Polistes Anaphlylaxis 3.54 Negative Positive (0.001 mcg/mL) 15 m
10 42 M Polistes Anaphlylaxis 28.9 Negative Positive (0.001 mcg/mL)
F, female; M, male; sIgE, specific IgE; m, month. 
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received immunotherapy for almost 5 years (n=12) (Table 2). 
No baseline determinations were available for this series, as 
treatments began before starting the study protocol. In the first 
subgroup, 4 patients were allergic to Apis and 2 patients to 
Wasps. In the group who finished VIT, 8 patients were allergic 
to Apis, 2 patients to Polistes, 1 to Vespula and 1 patient to both 
Vespula and Polistes.
Accidental stings were registered during the follow-up period 
in order to correlate clinical protection with BAT results.
All the individuals involved were informed and signed the in-
formed consent.
BAT
The method of BAT is described above.17,32,33 The analyses 
were performed within 24 hours of sampling (heparinized 
tubes; Vacutest Kima, Arzergrande,Italy). The whole blood was 
distributed in aliquots and pre-incubated for 10 minutes at 
37°C with a stimulation buffer containing IL-3 (3 ng/mL, Ther-
mo Scientific, Rockford, IL, USA). Straightaway, the samples 
were stimulated for 20 minutes at 37°C in a 100-µL water bath 
containing the tested stimulus: positive and negative controls 
as well as serial dilutions of commercial venom extracts (Alk-
Abello, Madrid, Spain). The extraction solvent was used as a 
negative control. The chemotactic peptide fMLP (N-formyl-
methionyl-leucyl-phenylalanine) working solution was tested 
as a positive control (Sigma-Aldrich, St. Louis, MO, USA). The 
venom dose-response curve was tested in each BAT and in-
cluded 4 final concentrations (25, 100, 500, and 1,000 ng/mL), 
selected as explained below. After the incubation process, the 
samples were left on ice for 5 minutes. A double surface stain-
ing with 10 µL of each monoclonal antibody was employed ac-
cording to the following strategy: CD203c-PE (Beckman Coult-
er, Brea, CA, USA) for gating the basophil population and 
CD63-FITC (Beckman Coulter) for measuring basophil activa-
tion. After staining, the samples were incubated for 20 minutes 
at 4°C, light protected, lysed for 10 minutes (Optilyse C, Beck-
man Coulter), centrifuged at 250×g for 5 minutes and washed. 
After decanting the supernatant, the samples were re-suspend-
ed in 400 µL of PBS and analyzed within 1 hour using flow cy-
tometry. The basophils were gated as CD203c-positive cells, as 
many as 500 events per sample, and CD63 co-expression was 
measured. The analysis was performed on a FC500 flow cytom-
eter using MXP and Kaluza softwares (Beckman Coulter).
Dose-response curve
To select adequate concentrations, a wide dose-response curve, 
from 2.5 to 5,000 ng/mL (2.5, 5, 10, 25, 100, 500, 1,000, 2,500, and 
5,000 ng/mL) was basally tested in 20 venom allergic patients 
complaining of systemic reactions. The criterion for positive re-
sults was the one described above for allergic patients, perform-
ing ROC-curves and using the same laboratory technique.18-20,23 
So, it was required that after adding the venom to the sample, a 
minimum of 15% of basophils became activated (measured as 
CD63 expression), after subtracting the basal activation seen on 
Table 2. Cross-sectional series
Patient Age Gender Venom Clinical picture BAT Field sting
3 years       
   1 47 M Apis Anaphylaxis Neg No
   2 66 F Vespula Anaphylaxis Neg No
   3 48 F Apis Anaphylaxis Neg Tolerated
   4 18 M Apis Anaphylaxis Neg Tolerated
   5 58 F Apis Urticaria Neg No
   6 47 M Vespula Anaphylaxis Neg  No
5 years       
   7 44 M Apis Anaphylaxis Neg Tolerated
   8 60 M Apis Anaphlylaxis Neg No
   9 46 F Apis Anaphylaxis Neg No
   10 15 M Polistes Anaphlylaxis Neg No
   11 58 M Polistes Anaphylaxis Neg Tolerated
   12 56 M Vespula Anaphlylaxis Positive Systemic rx
   13 69 F Apis Urticaria Positive Tolerated
   14   57 M Vesp/Pol Anaphlylaxis Positive Systemic rx
   15 62 M Apis Anaphylaxis Neg No
   16 67 M Apis Anaphlylaxis Neg Tolerated
   17 34 M Apis Anaphlylaxis Neg No
   18 48 M Polistes Anaphlylaxis Neg No
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the negative control. It was also desirable that the negative con-
trol did not exceed the 5% of basally activated basophils and that 
the positive control almost doubled the negative. According to 
this criterion, 3 of the patients were nonresponsive to the posi-
tive control and 41.66% of the series showed positive results for 
concentrations equal to or over 25 ng/mL; 50% over 100 ng/mL; 
91.66% over 500 ng/mL; and all responsive patients over 1,000 
ng/mL. The same curve was tested in 10 individual controls. No 
positive BAT results were found in any health controls, even for 
the highest concentration of 5,000 ng/mL.
Based on these results, in order to optimize the assay protocol 
in terms of efficiency, 4 concentrations were tested in all the 
analyses conducted throughout the VIT period: 25, 100, 500, 
and 1,000 ng/mL. 
In the cross-sectional studies carried out in patients who re-
ceived treatment during more than 3 years and those who com-
pleted 5 years of VIT, 2,000 and 5,000 ng/mL concentrations 
were also tested (dose-response curve for cross-sectional as-
says: 25, 100, 500,1,000, 2,000, and 5,000 ng/mL). 
Statistical analysis
The statistical analysis was performed with IBM SPSS Statis-
tics 19.00. Basophil activation was measured as the percentage 
of CD63+ basophils (basophil reactivity) for 4 different concen-
trations from the 8 tests conducted throughout the VIT period. 
The repeated measures ANOVA was applied to evaluate chang-
es in basophil activation during VIT (The activation results ob-
tained with all the concentrations tested at each time of analy-
sis were compared in blocks to those of the other times of anal-
ysis). Mauchly’s test of sphericity (The condition where the vari-
ances of the differences between all combinations of related 
groups are equal) indicated that the assumption of sphericity 
was violated, and therefore, a Greenhouse-Geisser correction 
was used. The Q-Q plot (quantile-quantile plot) and the Shap-
iro-Wilk test were used for checking normality. A P value of ≤
0.05 was required for statistical significance.
RESULTS
Prospective series
With regard to basophil reactivity during VIT, an early de-
crease in basophil activation was observed within the first 3 
months of treatment, compared to pre-treatment levels. This 
decrease was not maintained 6 to 18 months of treatment, but 
it was assessed again after 2 years of treatment and maintained 
throughout the remaining 3 years of VIT. The dose-response 
shaped (Fig. 1) according to these results was observed for all 
the concentrations tested and similar for all the series of pa-
tients (Fig. 2). As a result, the increase in venom concentrations 
was related to major basophil activation values.
Analyzing the results at each analysis time (Fig. 2), a signifi-
cant decrease in basophil activation was found in 3m (P=0.046) 
(3 months of treatment) in comparison to pre-treatment levels. 
This trend of early decrease in basophil reaction was also ob-
served in 1m, although it did not achieve significance (P=  
0.056). As mentioned above, this decrease was not maintained 
at intermediate times of treatment. Subsequently, significant 
differences in basophil activation levels were observed between 
the low activation levels assessed in 3m and the increase in ba-
sophil activation found in 6m (P=0.042) (Figs. 1 and 2). A sig-
nificant decrease in basophil activation was also found after 2 
years of treatment (24m), until the completion of the 5-year VIT 
period (60m), similar to that described for the first three 
months of treatment. Significant differences were observed be-
tween 18m (when basophil activation levels did not differ sig-
nificantly from pre-treatment levels) and 24m (P=0.05) (after 
which the activation reduction was maintained throughout the 
rest of VIT). The described behavior of basophil activation ex-
plains the negativization of BAT results during the treatment, 
mainly in the assays performed at the first months of VIT and 2 
years after VIT treatment, until completing VIT (Table 3).
The ratio of tests that met the positivity criterion was also ana-
lyzed. It was not the objective of the study to evaluate the quali-
tative parameter of positivity, more important for diagnostic 
purpose than for monitoring VIT. However, at certain times of 
treatment, although the reduction in the CD63+ basophil per-
centage was not significant with regard to basal values, the acti-
vation results decreased below the positivity criterion used to 
discriminate healthy individuals from allergic patients. BAT 
negativization at the beginning of VIT is more evident for the 
lower concentrations tested and indicates a decrease in baso-
phil sensitivity. For the highest concentrations the negativiza-
tion was observed in the last years of treatment. So, when the 
results for the concentration of 100 ng/mL were analyzed sepa-
rately, there were early decreases in basophil reactivation in 1m 
and 6m with regard to basal values, which were not evident for 
500 ng/mL at both time points (Fig. 3). Then, before beginning 
VIT, 62.15% of the total tests performed were positive, in con-
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trast to 23.33% in 1m, 28% in 3m, 30% in 6m, 38.8% in 12m, 
15.78% in 18m, and 21.05% in 24m. In the last time point (60m), 
no positive results were obtained. 
Accidental stings were registered during the follow-up period 
in order to determine if there is a correlation between activa-
tion rates and clinical protection. Two patients were stung dur-
ing the build-up phase (in the fifth and sixth weeks of the proto-
col), 2 patients at the 12th month of treatment and one last at 
the 15th, respectively (Table 1). None of them reported system-
ic reactions, and no remarkable changes in basophil activation 
were found in comparison to subsequent analysis results. 
Cross-sectional series
In the group of 6 patients who completed at least 3 years of 
VIT, all the patients presented negative BAT results, and 2 pa-
tients reported good tolerance to spontaneous stings (Table 2).
In the subgroup of 12 patients who completed 5 years of VIT, 9 
patients presented negative BAT results throughout the dose-
response curve, including high concentrations, 4 of whom re-
ported good clinical tolerance to spontaneous stings (Table 2). 
Three patients presented positive results (1 patient for Apis, 1 
patient for Polistes, and 1 poli-sensitized patient for both Vespu-
la and Polistes), and the last 2 reported systemic reactions to 
field stings. In these 2 cases, activation was over 15% of the ba-
sophil population for as low a concentration as 25 ng/mg, 
reaching levels of 90% for 1,000 ng/mL. The clinical tolerance of 
the patient allergic to Apis who was not stung again is unknown.
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Table 3. BAT results expressed as positive or negative in the prospective series 
at a concentration of 500 ng/mL
Patient 0 m 1 m 3 m 6 m 12 m 18 m 24 m 60 m
  1 + - - + + - - -
  2 + + - + +
  3 + - - + + - + -
  4 - - + + -
  5 + + + - + - -
  6 + + - - -
  7 + - - - -
  8 + - - - -
  9 + - - -
10 + - - + - - -
White cells, the results are not valuable for this patient at this concentration.
m, month; +, positive; -, negative.
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Although similar studies concerning VIT monitoring by using 
BAT have been published, in this work the longitudinal controls 
throughout a complete 5 years period of treatment were per-
formed more frequently than those previously reported, and a 
wider range of concentrations was tested. The close monitoring 
carried out in this study can in part clarify discordant results 
among several studies in terms of changes in basophil activa-
tion during VIT. The results of the intermediate-and long-term 
cross-sectional studies support the results obtained in the pro-
spective analysis.
With regard to the treatment length necessary to observe sig-
nificant changes in basophil activation, according to previous 
reports, we found no significant decrease in basophil activation 
in the analysis performed 623 and 12 months after the initiation 
of VIT;28 however, it was significantly observed 3 months after 
starting the maintenance dose, and nearly significant in the first 
month. Actually, the studies by Ebo et al.24 showed an early sig-
nificant decrease in basophil activation immediately after a 
5-day semi-rush schedule, but only for submaximal concentra-
tions (10 ng/mL), which represents a 10-fold decrease in baso-
phil sensitivity. In our and other series after 6 months of treat-
ment, a significant decrease was observed for 10 and 100 ng/
mL,24,30 but not for a maximal concentration of 10,000 ng/mL.24 
In fact, in our series, the early decrease in basophil activation 
was more evident when analyzed at a concentration of 100 ng/
mL, but not for the highest concentrations tested (Fig. 3). Then, 
this drop in basophil activation in the first year can be over-
looked if submaximal concentrations are not tested.
On the other hand, in order to adequately interpret basophil 
activation results obtained in each time of analysis, it must be 
taken into account that basophil activation values can be influ-
enced by each patient’s basophil sensitivity threshold. As seen 
in the prospective series and in the group of 20 patients where 
the initial dose-response curve was performed, several patients 
showed high responsiveness rates for low concentrations, in 
comparison to those who needed more quantity of allergen to 
become activated. To avoid such interference with the evalua-
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Fig. 3. Changes in basophil activation at 1 and 6 months after beginning treatment at concentrations of 100 and 500 ng/mL. The proportion of basal activation re-
sults is represented in the upper part of the box-plot, and the proportion after the treatment in the lower. (A) changes at 1 month of treatment at 100 ng/mL; (B) 
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tions tested each time were analyzed in blocks by repeated 
measures ANOVA which allows the evaluation of the global 
evolution of basophil response during the VIT and helps over-
come this problem. Nevertheless, other analysis methods, such 
as the CD-sens, which was not performed in this study, can 
have also been adequate in this study.
In our study, early changes in basophil activation were not 
maintained between 6 and 18 months of treatment; however, a 
significant decrease in basophil activation was observed once 
again after 2 years of treatment (or 1 and a half years for several 
patients, in the person-to-person analysis). In the cross-sec-
tional controls performed in the third and fifth years of treat-
ment, results were also comparable. Ebo et al.24 found similar 
results in cross-sectional controls of patients treated for 3 years, 
which shows significantly lower activation levels than the pre-
treatment levels in other series.
With regard to the clinical relevance of basophil activation lev-
els, a significant decrease in basophil reactivity in patients who 
tolerated sting challenge,26,28,29 and field stings30 have  been asso-
ciated with a good predictive value for clinical protection. This 
correlation could not be assessed in our series because few field 
stings have been reported by our patients (Tables 1 and 2). In fact, 
VIT monitoring by using BAT was considered to obtain informa-
tion about the clinical evolution of patients during VIT while dis-
pensing the challenge. This fact limits conclusions about clinical 
protection presumably achieved by the patients in whom the de-
crease in basophil activation was found to be statistically signifi-
cant and whose basophil behavior was similar to those of previ-
ously reports for patients who tolerated re-stings.26,28-30 In the 
group of patients treated for almost 5 years, BAT was negative in 
75% of patients, and those who suffered from systemic reactions 
after completing VIT showed positive BAT results at the lowest 
concentration tested. It would not be practicable to monitor VIT 
so closely using challenge testing. Further studies in larger popu-
lations are needed to confirm our results. 
Currently, it is not possible to fully explain the reproducible 
activation increase in the intermediate-term analysis (6 to 18 
months of treatment). A similar response has been described in 
a previous study on sublingual immunotherapy (SLIT) with la-
tex, where no significant activation changes in basophil activa-
tion were observed after 1 year of treatment, but were found af-
ter 2 years.34 Again, no early decrease in basophil activation was 
observed after 4 months of grass SLIT35,36 and 6 months of 
peach SLIT;37 in fact, an increase was observed in the last study. 
A plausible pathophysiological explanation for these results 
could be immunological changes observed in the early phases 
of immunotherapy with foods and other allergens, such as the 
allergen-specific IgE increase,38-41 possibly resulting in a reduc-
tion in the basophil responsiveness threshold or the antigen-
specific CD4+ T-cell proliferation induced by basophils.42,43 In-
deed, previous studies have shown that CD63 expression does 
not always reflect mediator release,44 as assessed by in vitro stud-
ies and good clinical tolerance to stings. This fact probably re-
flects an initial desensitization of basophils, where signalling cel-
lular activation still works, but degranulation does not take 
place. We are currently conducting assays where basophil acti-
vation and histamine release are measured simultaneously in 
order to clarify the significance of basophil responsiveness in 
these intermediated phases of VIT (data not shown). Thus, far 
from concluding that BAT is not a useful method to monitor 
specific immunotherapy,35,36 the reproducible assessment of 
these immunological changes, found in all the patients prospec-
tively examined (Fig. 2), is probably showing the initial stages of 
a long-lasting protective effect of this treatment. Thus, BAT re-
sults might be carefully interpreted after taking into account the 
length of the treatment and the venom concentration tested at 
each analysis time, which should be adequate to such length. 
Different responses between individual patients could indicate 
a suboptimal response to immunotherapy, and therefore, early 
therapeutic modifications can be made, such as increasing the 
maintenance dose and the therapeutic period, or adding coad-
jutant drugs, such as omalizumab or epinephrine as a rescue. 
Considering the best way to monitor the individual response 
to VIT, it must be taken into account that basophil threshold 
sensitivity varies, not only through the time, but also among pa-
tients. Hence, a dose-response curve is more sensitive to evalu-
ate changes in basophil activation throughout the treatment 
period. As mentioned above, 41.66% of the 20 patients, in 
whom the complete dose-response curve (2.5 to 5,000 ng/mL) 
was basally created, showed positive results at a concentration 
of 25 ng/mL. Therefore, testing at lower concentrations could 
be helpful in monitoring more sensitive patients, especially in 
the early phases of VIT. A 4-concentration dose-response curve 
is proposed to be tested at the first 3 years of VIT (25, 100, 500, 
and 1,000 ng/mL). On a long-term basis, after 3 years of treat-
ment, testing at higher venom concentrations (2,000 and 5,000 
ng/mL) is advisable to evaluate the risk of anaphylaxis. As Zit-
nik et al.30 described, patients with worse tolerance in the build-
up phase showed a greater value of 0.1/1 index for basophil ac-
tivation.
Finally, although more longitudinal comprehensive studies 
would be of great interest, the activation results in the interme-
diate-and long-term changes in basophil reactivity suggest that 
BAT could help monitor VIT safely and effectively. BAT can be 
performed at any time as needed in order to detect nonrespon-
sive patients and to determine the need to take additional ther-
apeutic measures.
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